CONTENTS:
• What can we learn from the failure of yet another 'miracle cure' for addiction? Humphreys K., p. 237-239.
• 100 Years Ago in Addiction Science: a modest initiative with serious intent. Edwards G., p. 240.
• FOR DEBATE: Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction? Ambermoon P., Carter A., Hall W., Dissanayaka N., O'Sullivan J., p. 241-247.
• Dopamine is not dopamine. Soyka M., p. 248.
• Addiction as aberrant learning-evidence from Parkinson's disease. Dagher A., p. 248-250.
• Compulsive use of dopamine replacement therapy in Parkinson's disease: insights into the neurobiology of addiction. Brown R.M., Lawrence A.J., p. 250-251.
• Compulsive use of dopamine replacement therapy among Parkinson's disease patients: if it looks like a duck, swims like a duck and quacks like a duck. Kaye S., p. 251-253.
• Stimulating debate in the field of addiction. Carter A., Hall W., Ambermoon P., Dissanayaka N., O'Sullivan J., p. 253.
• Addiction Research Centres and the Nurturing of Creativity. Monitoring the European drug situation: the ongoing challenge for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Griffiths P., Mounteney J., Lopez D., Zobel F., Gotz W., p. 254-258.
• Top priorities for alcohol regulators in the United States: protecting public health or the alcohol industry? Mart S.M., p. 259-262.
• DSM criteria for tobacco use disorder and tobacco withdrawal: a critique and proposed revisions for DSM-5. Baker T.B., Breslau N., Covey L., Shiffman S., p. 263-275.
• Commentary on Baker et al. (2012): Assessing dependence-are specific criteria for nicotine enough or do we need to consider its forms of administration? Fagerstrom K., p. 276-277.
• Psychosocial therapeutic interventions for volatile substance use: a systematic review. Maclean S., Cameron J., Harney A., Lee N.K., p. 278-288.
• Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis. Kelly J.F., Hoeppner B., Stout R.L., Pagano M., p. 289-299.
• Commentary on Kelly et al. (2012): Multiple mediation-many mechanisms signal more questions. Kaskutas L.A., p. 300.
• Does sponsorship improve outcomes above Alcoholics Anonymous attendance? A latent class growth curve analysis. Witbrodt J., Kaskutas L., Bond J., Delucchi K., p. 301-311.
• The relation between hypothalamic-pituitary-adrenal (HPA) axis activity and age of onset of alcohol use. Evans B.E., Greaves-Lord K., Euser A.S., Franken I.H., Huizink A.C., p. 312-322.
• Subjective measures of binge drinking and alcohol-specific adverse health outcomes: a prospective cohort study. Paljarvi T., Makela P., Poikolainen K., Suominen S., Car J., Koskenvuo M., p. 323-330.
• Age differences in diagnostic criteria of DSM-IV alcohol dependence among adults with similar drinking behaviour. Pabst A., Kraus L., Piontek D., Baumeister S.E., p. 331-338.
• A longitudinal study of substance use and violent victimization in adulthood among a cohort of urban African Americans. Doherty E.E., Robertson J.A., Green K.M., Fothergill K.E., Ensminger M.E., p. 339-348.
• Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Mehta S.H., Sudarshi D., Srikrishnan A.K., Celentano D.D., Vasudevan C.K., Anand S., et al., p. 349-358.
• Commentary on Mehta et al. (2012): Natural history of injecting drug use. Hickman M., Vickerman P., Degenhardt L., p. 359-360.
• Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. Ling W., Shoptaw S., Hillhouse M., Bholat M.A., Charuvastra C., Heinzerling K., et al., p. 361-369.
• Commentary on Ling et al. (2012): The PROMETA treatment does not reduce methamphetamine use. Sofuoglu M., p. 370-371.
• Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Larney S., Toson B., Burns L., Dolan K., p. 372-380.
• Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. van Gastel W.A., Wigman J.T., Monshouwer K., Kahn R.S., van Os J., Boks M.P., et al., p. 381-387.
• The effect of methadone on emotional reactivity. Savvas S.M., Somogyi A.A., White J.M., p. 388-392.
• Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Bukten A., Skurtveit S., Gossop M., Waal H., Stangeland P., Havnes I., et al., p. 393-399.
• Examining the predictive validity of low-risk gambling limits with longitudinal data. Currie S.R., Hodgins D.C., Casey D.M., El-Guebaly N., Smith G.J., Williams R.J., et al., p. 400-406.
• The effect of tobacco control policies on smoking prevalence and smoking-attributable deaths. Findings from the Netherlands SimSmoke Tobacco Control Policy Simulation Model. Nagelhout G.E., Levy D.T., Blackman K., Currie L., Clancy L., Willemsen M.C., p. 407-416.
• Delay discounting by adolescents experimenting with cigarette smoking. Reynolds B., Fields S., p. 417-424.
• The association between exposure to point-of-sale anti-smoking warnings and smokers' interest in quitting and quit attempts: findings from the International Tobacco Control Four Country Survey. Li L., Borland R., Yong H.H., Hitchman S.C., Wakefield M.A., Kasza K.A., et al., p. 425-433.
• Do components of current 'hardcore smoker' definitions predict quitting behaviour? Ip D.T., Cohen J.E., Bondy S.J., Chaiton M.O., Selby P., Schwartz R., et al., p. 434-440.
• A damage/benefit evaluation of addictive product use. Bourgain C., Falissard B., Blecha L., Benyamina A., Karila L., Reynaud M., p. 441-450.
• Concurrent use of tobacco and khat: added burden on chronic disease epidemic [Letter to the editor]. Al'absi M., Grabowski J., p. 451-452.
• 100 years ago in addiction science. Edwards G., p. 459-460.